0001209191-21-047756.txt : 20210722
0001209191-21-047756.hdr.sgml : 20210722
20210722163728
ACCESSION NUMBER: 0001209191-21-047756
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210720
FILED AS OF DATE: 20210722
DATE AS OF CHANGE: 20210722
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EHRLICH JASON
CENTRAL INDEX KEY: 0001754049
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38682
FILM NUMBER: 211108028
MAIL ADDRESS:
STREET 1: 1200 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kodiak Sciences Inc.
CENTRAL INDEX KEY: 0001468748
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270476525
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1200 PAGE MILL RD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
BUSINESS PHONE: 650-281-0850
MAIL ADDRESS:
STREET 1: 1200 PAGE MILL RD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
FORMER COMPANY:
FORMER CONFORMED NAME: Oligasis, LLC
DATE OF NAME CHANGE: 20090721
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-20
0
0001468748
Kodiak Sciences Inc.
KOD
0001754049
EHRLICH JASON
1200 PAGE MILL ROAD
PALO ALTO
CA
94304
0
1
0
0
See Remarks
Common Stock
2021-07-20
4
S
0
2234
85.7604
D
57949
D
Common Stock
2021-07-20
4
S
0
4716
86.5215
D
53233
D
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $85.085 to $86.085, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $86.09 to $86.89, inclusive.
Chief Medical Officer and Chief Development Officer
/s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
2021-07-22